Clinical Trial Update: Safety, Pharmacokinetics, and Preliminary Efficacy Study of CDZ173 in Patients With Primary Sjögren's Syndrome [Phase 2]

View source ↗

Summary

Phase 2 trial update for CDZ173 in Primary Sjögren's Syndrome with safety, pharmacokinetics, and preliminary efficacy data posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• _primary Sicca Syndrome _

Drugs mentioned

• CDZ173 (CDZ173)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Primary Sjögren's Syndrome | Phase 2 | Status: COMPLETED | Results posted: 2019-10-18